<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030653</url>
  </required_header>
  <id_info>
    <org_study_id>09010</org_study_id>
    <nct_id>NCT01030653</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Voriconazole in Obese Subjects</brief_title>
  <official_title>Pharmacokinetics of Voriconazole in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manjunath Prakash Pai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TKL Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obese subjects may require a higher fixed oral maintenance dosing regimen of voriconazole
      compared to normal weight subjects to achieve comparable plasma exposures. The current study
      is designed to address this issue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of obesity has increased tremendously in the past two decades. An estimated 1
      out of 5 persons in the United States are classified as obese. Under representation of obese
      patients in pharmacokinetic trials grossly limit generalizability of drug dosing
      recommendations in this emerging population. No published pharmacokinetic studies of
      voriconazole dosing in patients with obesity currently exist in the literature.
      Specifically,voriconazole pharmacokinetic data from subjects with a body mass index (BMI) ≥
      35 kg/m2(Class II and III obesity) are limited.

      Voriconazole is available as both an intravenous and oral formulation. Anecdotal experience
      suggest that the use of oral voriconazole to be significantly more prevalent that that of
      intravenous therapy. The current oral recommended dosing regimen for voriconazole includes
      use of 200 mg every 12 hours for patients who are over 40 kg. The dosage can be increased to
      300 mg by mouth every 12 hours in situations where a sufficient clinical response is not
      noted. A weight based dosing strategy is also utilized in patients with more serious
      infections (3-6 mg/kg IV Q 12 hours) such as invasive aspergillosis. Voriconazole
      demonstrates non-linear pharmacokinetics and so dosing based on total body weight may result
      in non-dose proportional exposure. For example, a 1.5 fold dose increment in voriconazole
      from 200 mg to 300 mg every 12 hours results in a 2.5 fold increase in exposure. The most
      appropriate body size descriptor is unknown (i.e. ideal body weight, fat free weight, lean
      body weight, etc.) for most antimicrobials, including voriconazole. As a consequence, the
      appropriateness of weight-based voriconazole dosage selection in obese patients is not known.
      Intuitively, weight based dosing (on total body weight) in this population could lead to
      higher than expected exposures (non-linear pharmacokinetics) and lead to potential adverse
      events. Therapeutic drug monitoring is increasingly advocated as a system to improve
      voriconazole dosing. However, an assay to measure voriconazole concentrations in the clinic
      is not routinely available. Hence, the current pilot study proposes to characterize the
      pharmacokinetic profile of voriconazole in obese subjects using two fixed dose regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-State Cmax and Cmin of Two Voriconazole Dosing Regimens</measure>
    <time_frame>Day 5</time_frame>
    <description>Cmax is the maximum concentration, and Cmin is the minimum concentration. These measurements are based on analysis of plasma. The units shown are milligrams of voriconazole per liter of plasma. The two dosing regimens are:
a loading dose (400 mg x 2 doses, day 1) and maintenance doses (200 mg every 12 hours x 7 doses) in obese subjects.
a loading dose (400 mg x 2 doses, day 1) and maintenance doses (300 mg every 12 hours x 7 doses) in obese subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio of the AUC Between the High and Low Dose Voriconazole</measure>
    <time_frame>14 days</time_frame>
    <description>AUC is the area under the concentration-time curve. The Geometric Mean Ratio and 90% confidence interval around this value permit an assessment of the bioequivalence of two dosing regimens in the same group. The geometric mean is computed based on the ratio of the AUC value from the high dose compared to the AUC value from the low dose for each individual. This ratio provides a more robust interpretation of the differences between the two dosing arms because each individual serves as their own control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Curve Over the Dosing Interval for All Participants While on the High Dose and Low Dose Interventions.</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Voriconazole low dose first then high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voriconazole high dose first then low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole low dose</intervention_name>
    <description>Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses</description>
    <arm_group_label>Voriconazole low dose first then high dose</arm_group_label>
    <arm_group_label>Voriconazole high dose first then low dose</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole high dose</intervention_name>
    <description>Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses</description>
    <arm_group_label>Voriconazole low dose first then high dose</arm_group_label>
    <arm_group_label>Voriconazole high dose first then low dose</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. males and females, 18 to 50 years of age;

          2. non-smoking or light-smoking (≤5 cigarettes per day) volunteers;

          3. BMI ≥ 35 kg/m2;

          4. female subjects of childbearing potential either surgically sterilized, using an
             effective method of contraception (diaphragm, cervical cap, condom) or agree to
             abstain from sex from time of prestudy screening, during entire study period and 1
             week following the study period.

        Exclusion Criteria:

          1. History of significant hypersensitivity reaction or intolerance to voriconazole,
             fluconazole,itraconazole, posaconazole, or ketoconazole ;

          2. history of significant clinical illness requiring pharmacological management;

          3. abnormal serum electrolyte or complete blood count requiring further clinical work-up;

          4. transaminases (AST or ALT) &gt;2.5 x upper limit of normal;

          5. estimated creatinine clearance &lt;50 mL/min (Cockcroft-Gault equation);

          6. positive urine pregnancy test (if female);

          7. abnormal electrocardiogram (ECG) as judged by study physician;

          8. unable to tolerate venipuncture and multiple blood draws;

          9. clinically significant abnormal physical examination defined as a physical finding
             requiring further clinical work-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manjunath P Pai, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TKL Research Inc</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007 Aug;51(8):2741-7. Epub 2007 Jun 4.</citation>
    <PMID>17548489</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2009</study_first_posted>
  <results_first_submitted>June 23, 2011</results_first_submitted>
  <results_first_submitted_qc>December 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2017</results_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Manjunath Prakash Pai</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Voriconazole</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Obese</keyword>
  <keyword>Healthy Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinical research unit, subjects recruited over a 6 month period</recruitment_details>
      <pre_assignment_details>This was a healthy volunteer study that did not require any pre assignment study procedures. 10 participants were consented but 8 were sufficient to complete the study. The remaining two subjects were not assigned to any arm, comparable to a screen failure. No intervention other than consent and screening occurred for these two subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Voriconazole High Dose First Then Low Dose</title>
          <description>Active: Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Two Fixed Maintenance Doses ( 300 mg Every 12 Hours x 7 Doses) followed by a 7-day washout period then a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses ( 200 mg Every 12 Hours x 7 Doses)</description>
        </group>
        <group group_id="P2">
          <title>Voriconazole Low Dose First Then High Dose</title>
          <description>Active: Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Two Fixed Maintenance Doses ( 200 mg Every 12 Hours x 7 Doses) followed by a 7-day washout period then a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses ( 300 mg Every 12 Hours x 7 Doses)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Loading Dose &amp; First Maintenance Regimen</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>7-Day Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Loading Dose &amp; 2nd Maintenance Regimen</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Voriconazole High Dose First Then Low Dose</title>
          <description>Both voriconazole arms are shown as a single group because the same individuals received both arms of the intervention in a cross-over design.</description>
        </group>
        <group group_id="B2">
          <title>Voriconazole Low Dose First Then High Dose</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steady-State Cmax and Cmin of Two Voriconazole Dosing Regimens</title>
        <description>Cmax is the maximum concentration, and Cmin is the minimum concentration. These measurements are based on analysis of plasma. The units shown are milligrams of voriconazole per liter of plasma. The two dosing regimens are:
a loading dose (400 mg x 2 doses, day 1) and maintenance doses (200 mg every 12 hours x 7 doses) in obese subjects.
a loading dose (400 mg x 2 doses, day 1) and maintenance doses (300 mg every 12 hours x 7 doses) in obese subjects.</description>
        <time_frame>Day 5</time_frame>
        <population>The same subjects were analyzed in a cross-over design at two dose levels</population>
        <group_list>
          <group group_id="O1">
            <title>Voriconazole Lower Dose</title>
            <description>Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg or Every 12 Hours x 7 Doses)</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole Higher Dose</title>
            <description>Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg or Every 12 Hours x 7 Doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-State Cmax and Cmin of Two Voriconazole Dosing Regimens</title>
          <description>Cmax is the maximum concentration, and Cmin is the minimum concentration. These measurements are based on analysis of plasma. The units shown are milligrams of voriconazole per liter of plasma. The two dosing regimens are:
a loading dose (400 mg x 2 doses, day 1) and maintenance doses (200 mg every 12 hours x 7 doses) in obese subjects.
a loading dose (400 mg x 2 doses, day 1) and maintenance doses (300 mg every 12 hours x 7 doses) in obese subjects.</description>
          <population>The same subjects were analyzed in a cross-over design at two dose levels</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" lower_limit="1.70" upper_limit="3.28"/>
                    <measurement group_id="O2" value="4.16" lower_limit="2.76" upper_limit="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.46" upper_limit="1.44"/>
                    <measurement group_id="O2" value="1.76" lower_limit="1.17" upper_limit="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio of the AUC Between the High and Low Dose Voriconazole</title>
        <description>AUC is the area under the concentration-time curve. The Geometric Mean Ratio and 90% confidence interval around this value permit an assessment of the bioequivalence of two dosing regimens in the same group. The geometric mean is computed based on the ratio of the AUC value from the high dose compared to the AUC value from the low dose for each individual. This ratio provides a more robust interpretation of the differences between the two dosing arms because each individual serves as their own control.</description>
        <time_frame>14 days</time_frame>
        <population>This is a comparison of the same group analyzed through a cross-over design of two voriconazole dosing regimens</population>
        <group_list>
          <group group_id="O1">
            <title>Voriconazole High : Low Dose</title>
            <description>Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg or Every 12 Hours x 7 Doses)
Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg or Every 12 Hours x 7 Doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio of the AUC Between the High and Low Dose Voriconazole</title>
          <description>AUC is the area under the concentration-time curve. The Geometric Mean Ratio and 90% confidence interval around this value permit an assessment of the bioequivalence of two dosing regimens in the same group. The geometric mean is computed based on the ratio of the AUC value from the high dose compared to the AUC value from the low dose for each individual. This ratio provides a more robust interpretation of the differences between the two dosing arms because each individual serves as their own control.</description>
          <population>This is a comparison of the same group analyzed through a cross-over design of two voriconazole dosing regimens</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.5" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Area Under the Curve Over the Dosing Interval for All Participants While on the High Dose and Low Dose Interventions.</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Voriconazole Lower Dose</title>
            <description>Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg or Every 12 Hours x 7 Doses)</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole Higher Dose</title>
            <description>Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg or Every 12 Hours x 7 Doses)</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Curve Over the Dosing Interval for All Participants While on the High Dose and Low Dose Interventions.</title>
          <units>hour*milligram/Liter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="9.21" upper_limit="23.1"/>
                    <measurement group_id="O2" value="29.2" lower_limit="19.4" upper_limit="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Voriconazole High Dose</title>
          <description>Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg or Every 12 Hours x 7 Doses)</description>
        </group>
        <group group_id="E2">
          <title>Voriconazole Low Dose</title>
          <description>Voriconazole Administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg or Every 12 Hours x 7 Doses)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study sample size was small.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Manjuanth Pai</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7346470006</phone>
      <email>amitpai@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

